



VentricHealth



Detect Heart Failure Earlier

The Vivio® System provides rapid, non-invasive identification of elevated LVEDP at the point of care.

First and only non-invasive LVEDP measurement.

Heart Failure Is Diagnosed Too Late

Heart failure affects 6.7 million Americans with 1 out of 4 developing heart failure in their lifetime.¹ Yet most patients are first diagnosed in the emergency room or in-hospital, after the disease has already progressed significantly.²

Left ventricular end-diastolic pressure (LVEDP), the clinical hallmark of heart failure, has historically only been measurable through invasive cardiac catheterization.

Until now.



A New Standard in Early Detection

Vivio® is the first and only non-invasive solution that definitively identifies elevated LVEDP bringing hospital-grade diagnostic insight into the primary care setting.

For Patients

- Decreased 30-day and one-year mortality.
- Decreased one-year, all-cause hospitalization.
- Increased overall quality of life.

For Clinicians

- Increased awareness of patient needs.
- Improved impact on quality of care and health outcomes.
- Increased ability to categorically diagnose and compliantly document heart failure.

For Health Plans

- \$21,800 one-year cost savings per patient.
- \$17,500 cost savings per initial diagnostic visit.^{3,4}
- Increased emphasis on equitable, patient-centric care.^{3,4}

References:

¹Bozkurt, Biykem. "HF stats 2024: Heart Failure Epidemiology and Outcomes Statistics an updated 2024 report from the Heart Failure Society of America." Journal of Cardiac Failure, vol. 31, no. 1, Jan. 2025, pp. 66–116, <https://doi.org/10.1016/j.cardfail.2024.07.001>.

²Curtis LH. Incidence and Prevalence of Heart Failure in Elderly Persons, 1994–2003. Archives of Internal Medicine. 2008;168(4):418. doi:<https://doi.org/10.1001/archinternmed.2007.80>.

³Ezekowitz JA, Kaul P, Bakal JA, Quan H, McAlister FA. Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics? European Journal of Heart Failure. 2011;13(2):142–147. doi:<https://doi.org/10.1093/eurjhf/hfq185>

⁴Urbich M, Globe G, Pantiri K, et al. A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020). PharmacoEconomics. 2020;38(11):1219–1236

Definitive Heart Failure Assessment: Now in Everyday Practice

Vivio's ability to accurately identify elevated LV filling pressure enables earlier diagnosis of both Stage B and C heart failure.

Earlier identification empowers earlier treatment with frontline medications like SGLT-2 inhibitors.

Vivio Key Advantages

- FDA-cleared Class II medical device.
- Non-invasive test completed in less than five minutes.
- Definitive measurement of LVEDP (filling pressure).
- Gold standard accuracy.
- 2.7x increase in HF diagnosis in primary care.⁵

Beyond Traditional Tools

Traditional methods, such as natriuretic peptides, echocardiography and clinical scoring systems, lack sensitivity or require specialist access.



"Since adopting the Vivio System in March 2024, we've been able to identify changes in heart function earlier and initiate treatment sooner. It has become a valued part of our primary care strategy and allows us to have a more engaging connection with our patients while putting the focus on total-person care. Our patients and primary care physicians appreciate the proactive approach."

Leah Dixon, PA-C, Desert Oasis Healthcare, Palm Springs CA

Vivio delivers definitive, actionable data at the point of care.

See more at TheVivioSystem.com

References:

⁵Ventric Health, data on file, 2026.

See Vivio in Action in Under 5 Minutes

Heart failure remains underdiagnosed in primary care, not due to lack of clinical expertise, but because LVEDP has required invasive measurement.

The Vivio® System changes that.



Request a Demo

See how quickly Vivio delivers actionable LVEDP data during a routine patient visit.

TheVivioSystem.com



117 E Colorado Blvd, Suite 510
Pasadena, CA 91105

©2026 Ventric Health

Vivio® is only available in the U.S.